One of the more cynical attacks on our industry goes something like this: “Taxpayers fund medical research through research grants, so they should get the benefits of any discoveries, not the greedy pharma companies.” I’m sure you’ve heard it. Politicians and pundits of all stripes love to reinforce the idea that pharma is gorging at the public trough – that all we do is gobble up federal grants as seed money for our outrageously priced nostrums.
Finding more information about your personal health or the health of your family has never been more meaningful than over the past year. For many individuals, patients and consumers, the need to address myriad questions and seek out additional areas of interest has become a quest. But in an age when information is ubiquitous and public health is top of mind, a new study on health fluency indicates that the road to such insight is now paved with multiple lanes and involves more than the traditional health care organizations and companies relied on before.
Placebo response is one of the most significant challenges faced by drug developers who are investigating new pain medications. According to a review of published chronic neuropathic pain trials, placebo responses have increased in magnitude over time, making it even more difficult to definitively demonstrate treatment advantage. Research has also shown that up to 60 percent of study participants may experience placebo-related analgesic responses and that these responses may be persistent.
Researchers at Northwestern University identified a compound that appears to reverse the ongoing degeneration of upper motor neurons associated with amyotrophic lateral sclerosis (ALS).
Moderna started development on a booster to the company’s Covid-19 vaccine, which is hoped to work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa.
This white paper from Abbott examines a cross-section of the global healthcare system leveraging primary research with 1,400+ respondents including patients, physicians, and administrators.
Shionogi & Co. is planning clinical trials by year-end 2020 for what may be one of Japan’s first domestically produced Covid-19 vaccines to reach the market, as the globe races to secure enough doses to battle the pandemic.
Outcome Health announced the launch of Who Saves Me?, a campaign to bring awareness to the overwhelming percentage of physicians who quietly suffer from burnout and mental health struggles.
BioSpace reviews some of the more interesting recently published scientific studies, including whether the Covid-19 virus relieve pain.
Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.